vs
RHYTHM PHARMACEUTICALS, INC.（RYTM）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
COMSCORE, INC.的季度营收约是RHYTHM PHARMACEUTICALS, INC.的1.6倍（$93.5M vs $57.3M），COMSCORE, INC.净利率更高（3.2% vs -83.0%，领先86.2%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（36.9% vs -1.5%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（48.5% vs 3.8%）
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
RYTM vs SCOR — 直观对比
营收规模更大
SCOR
是对方的1.6倍
$57.3M
营收增速更快
RYTM
高出38.4%
-1.5%
净利率更高
SCOR
高出86.2%
-83.0%
两年增速更快
RYTM
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.3M | $93.5M |
| 净利润 | $-47.5M | $3.0M |
| 毛利率 | 91.6% | 41.0% |
| 营业利润率 | -82.2% | 7.0% |
| 净利率 | -83.0% | 3.2% |
| 营收同比 | 36.9% | -1.5% |
| 净利润同比 | -9.6% | -3.7% |
| 每股收益（稀释后） | $-0.73 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RYTMSCOR
| Q4 25 | $57.3M | $93.5M | ||
| Q3 25 | $51.3M | $88.9M | ||
| Q2 25 | $48.5M | $89.4M | ||
| Q1 25 | $32.7M | $85.7M | ||
| Q4 24 | $41.8M | $94.9M | ||
| Q3 24 | $33.3M | $88.5M | ||
| Q2 24 | $29.1M | $85.8M | ||
| Q1 24 | $26.0M | $86.8M |
净利润RYTMSCOR
| Q4 25 | $-47.5M | $3.0M | ||
| Q3 25 | $-52.9M | $453.0K | ||
| Q2 25 | $-46.6M | $-9.5M | ||
| Q1 25 | $-49.5M | $-4.0M | ||
| Q4 24 | $-43.3M | $3.1M | ||
| Q3 24 | $-43.6M | $-60.6M | ||
| Q2 24 | $-32.3M | $-1.7M | ||
| Q1 24 | $-141.4M | $-1.1M |
毛利率RYTMSCOR
| Q4 25 | 91.6% | 41.0% | ||
| Q3 25 | 89.3% | 40.6% | ||
| Q2 25 | 88.6% | 40.6% | ||
| Q1 25 | 88.8% | 39.6% | ||
| Q4 24 | 90.9% | 42.4% | ||
| Q3 24 | 88.5% | 41.2% | ||
| Q2 24 | 89.9% | 39.5% | ||
| Q1 24 | 89.2% | 42.3% |
营业利润率RYTMSCOR
| Q4 25 | -82.2% | 7.0% | ||
| Q3 25 | -102.6% | 1.9% | ||
| Q2 25 | -93.4% | -1.9% | ||
| Q1 25 | -143.7% | -2.4% | ||
| Q4 24 | -98.6% | 4.1% | ||
| Q3 24 | -132.0% | -67.4% | ||
| Q2 24 | -139.2% | -2.2% | ||
| Q1 24 | -538.7% | -2.2% |
净利率RYTMSCOR
| Q4 25 | -83.0% | 3.2% | ||
| Q3 25 | -103.1% | 0.5% | ||
| Q2 25 | -96.1% | -10.6% | ||
| Q1 25 | -151.4% | -4.7% | ||
| Q4 24 | -103.6% | 3.3% | ||
| Q3 24 | -131.2% | -68.5% | ||
| Q2 24 | -110.9% | -2.0% | ||
| Q1 24 | -544.4% | -1.2% |
每股收益（稀释后）RYTMSCOR
| Q4 25 | $-0.73 | $9.50 | ||
| Q3 25 | $-0.82 | $-0.86 | ||
| Q2 25 | $-0.75 | $-2.73 | ||
| Q1 25 | $-0.81 | $-1.66 | ||
| Q4 24 | $-0.71 | $-0.47 | ||
| Q3 24 | $-0.73 | $-12.79 | ||
| Q2 24 | $-0.55 | $-1.19 | ||
| Q1 24 | $-2.35 | $-1.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.9M | $23.6M |
| 总债务越低越好 | — | $41.5M |
| 股东权益账面价值 | $139.1M | $111.4M |
| 总资产 | $480.2M | $407.7M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资RYTMSCOR
| Q4 25 | $388.9M | $23.6M | ||
| Q3 25 | $416.1M | $26.7M | ||
| Q2 25 | $291.0M | $26.0M | ||
| Q1 25 | $314.5M | $31.0M | ||
| Q4 24 | $320.6M | $29.9M | ||
| Q3 24 | $298.4M | $20.0M | ||
| Q2 24 | $319.1M | $14.7M | ||
| Q1 24 | $201.2M | $18.7M |
总债务RYTMSCOR
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益RYTMSCOR
| Q4 25 | $139.1M | $111.4M | ||
| Q3 25 | $148.8M | $-26.3M | ||
| Q2 25 | $-11.9M | $-21.7M | ||
| Q1 25 | $18.9M | $-13.5M | ||
| Q4 24 | $21.7M | $-8.3M | ||
| Q3 24 | $11.2M | $-2.7M | ||
| Q2 24 | $39.3M | $45.8M | ||
| Q1 24 | $61.6M | $51.4M |
总资产RYTMSCOR
| Q4 25 | $480.2M | $407.7M | ||
| Q3 25 | $506.9M | $406.9M | ||
| Q2 25 | $372.7M | $415.9M | ||
| Q1 25 | $386.7M | $421.5M | ||
| Q4 24 | $392.3M | $430.2M | ||
| Q3 24 | $363.6M | $412.5M | ||
| Q2 24 | $381.8M | $474.1M | ||
| Q1 24 | $258.7M | $477.7M |
负债/权益比RYTMSCOR
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-25.4M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | — | $2.9M |
| 自由现金流率自由现金流/营收 | — | 3.1% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.07× |
| 过去12个月自由现金流最近4个季度 | — | $21.8M |
8季度趋势，按日历期对齐
经营现金流RYTMSCOR
| Q4 25 | $-25.4M | $3.2M | ||
| Q3 25 | $-26.6M | $9.5M | ||
| Q2 25 | $-23.3M | $932.0K | ||
| Q1 25 | $-40.4M | $9.1M | ||
| Q4 24 | $-18.8M | $-10.0M | ||
| Q3 24 | $-25.2M | $12.5M | ||
| Q2 24 | $-29.1M | $8.7M | ||
| Q1 24 | $-40.7M | $6.9M |
自由现金流RYTMSCOR
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $9.4M | ||
| Q2 25 | — | $787.0K | ||
| Q1 25 | — | $8.7M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $6.6M |
自由现金流率RYTMSCOR
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 10.5% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | — | -10.8% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 10.0% | ||
| Q1 24 | — | 7.6% |
资本支出强度RYTMSCOR
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.3% |
现金转化率RYTMSCOR
| Q4 25 | — | 1.07× | ||
| Q3 25 | — | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RYTM
暂无分部数据
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
